JENRIN DISCOVERY - Key Persons
Job Titles:
- General Manager at Jefferson Corner Group
Ms. Alms serves as the General Manager at Jefferson Corner Group, and serves as the General Manager of Spinner Technologies She was a Venture Partner at yet2Ventures, responsible for life science investment analysis and pricing for the firm. She also founded and leads BrookDell BioVentures Management. She assisted in the creation of Spinner Technologies as a for-profit subsidiary of the University of Virginia Patent Foundation. Ms. Alms was a Licensing Associate at the University of Virginia Patent Foundation and Research Associate at Harvard Medical School. She has 15 years of experience sourcing, closing, managing, and exiting equity investments as well as building life science assets and companies.
Job Titles:
- Managing Director and CEO of BioAdvance
Ms. Schilberg, Managing Director and CEO of BioAdvance, has more than 20 years' experience in life sciences. Under her leadership as CEO, BioAdvance has invested $14 million in 25 seed-stage companies and 13 pre-seed projects focusing in areas including Alzheimer's disease, cancer, diabetes, obesity and infectious diseases. The portfolio companies have gone on to raise more than $900 million in additional funding and six have been sold. Ms. Schilberg's industry experience includes senior leadership positions at Cephalon, Incara Pharmaceuticals, Advanced Medicine (now Theravance) and Locus Discovery, Inc.
Before joining the industry, Ms Schilberg represented biopharmaceutical companies and universities as a partner with Morgan, Lewis & Bockius. She received a J.D. from the University of Virginia.
Dr. Souvignier conducts the scientific and business analysis of early-stage biomedical investment opportunities for Research Corporation Technologies (RCT) and also manages a portfolio of projects and investments for RCT. His areas of focus at RCT include oncology, pain, central nervous system disorders, diabetes and metabolic disease.
Job Titles:
- Is Director of Investments
Jennifer Hartt is Director of Investments, Health & Digital Health, for Ben Franklin. She directs all of Ben Franklin's life sciences investments in companies with technologies ranging from clinical healthcare IT, medical devices and diagnostics to therapeutics. Prior to joining Ben Franklin, Ms. Hartt was Associate Director of Business Development & Equity at the University of Pennsylvania.
Ms. Hartt holds a Master's in Biology and Bachelor's degree from the University of Pennsylvania.
Robert Chorvat, Ph.D., Chief Scientific Officer, led the Medicinal Chemistry effort and was responsible for the conception and synthesis of the proprietary peripherally selective compounds, as well as crafting the patent applications covering these agents. Bob has more than 30 years of leadership experience in the pharmaceutical industry where he headed medicinal chemistry groups at Searle/Monsanto, DuPont Medical Products, DuPont-Merck and DuPont Pharmaceuticals (now Bristol Meyers Squibb). Dr. Chorvat was also an adjunct professor at the University of Illinois School of Pharmacy, served on the Scientific Advisory Board of deCode Genetics (formerly MediChem Life Sciences), and as a consultant for Treventis Corp., Anakim Biologics and Academic Pharmaceuticlas, Inc. He has authored or co-authored about 40 peer-reviewed papers and three book chapters, and is the inventor on about 55 issued US patents. Bob received his Ph.D. from Illinois Institute of Technology, and his Bachelor of Science degree from Illinois Benedictine College
Job Titles:
- Chairman
- General Partner of SeVen Holdings
Mr. Barrett is General Partner of SeVen Holdings, LLC, a Southeast-based venture capital firm that provides equity capital to early and expansion stage companies with proprietary technology platforms or unique products addressing large markets. Mr. Barrett is also the managing General Partner of BVM Capital, which is the leadership company for venture funds: Louisiana Ventures, LP and Themelios Ventures, LP. He is a Co-founder of VC Experts, Inc. and is active in the strategic direction of the company.
Mr. Barrett received a master's degree in taxation from New York University School of Law. Prior to NYU Law, he earned a J.D. from Louisiana State University School of Law. He has a B.A. in Political Science from Southern Methodist University.
Mr. Gardner, Gardner Lewis Asset Management, has served as Chairman and Chief Executive Officer of Gardner Lewis Asset Management since the firm's founding. Previously, he was a lead Portfolio Manager with Friess Associates and its Brandywine Fund. Prior to joining Friess Associates, he worked as an Investment Analyst with Investments Orange Nassau, a Netherlands-based venture capital firm, with interests in both private and public companies. This position stemmed from employment with MBank, then a $20 billion bank holding company, where he analyzed companies as well as industry groups.
Mr. Gardner began his investment career at Lehman Brothers Kuhn Loeb (prior to the Shearson Merger). He received his B.B.A. in Finance from Southern Methodist University.